US9842411095 - YMAB (XNAS)
Y-MABS THERAPEUTICSCS INC Aktie
13,79 USD
Aktuelle Kurse von Y-MABS THERAPEUTICSCS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
YMAB
|
USD
|
20.09.2024 20:24
|
13,79 USD
| 14,00 USD | -1,50 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
-1,50 % | 0,36 % | 11,48 % | 15,79 % | -7,39 % | 163,67 % | -55,90 % |
Firmenprofil zu Y-MABS THERAPEUTICSCS INC Aktie
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Investierte Fonds
Folgende Fonds haben in Y-MABS THERAPEUTICSCS INC investiert:
Fonds | Vol. in Mio 49,58 | Anteil (%) 0,12 % |
Unternehmensdaten zur Y-MABS THERAPEUTICSCS INC Aktie
Name Y-MABS THERAPEUTICSCS INC
Firma Y-mAbs Therapeutics, Inc.
Symbol YMAB
Website https://www.ymabs.com
Heimatbörse
NASDAQ
ISIN US9842411095
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Michael Rossi
Marktkapitalisierung 638 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 230 Park Avenue, 10169 New York
IPO Datum 2018-09-21
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | YMAB |
Weitere Aktien
Investoren die Y-MABS THERAPEUTICSCS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024